Skip to main navigation Skip to search Skip to main content

Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia

  • Eitan Kugler
  • , Inbar Cohen
  • , Irina Amitai
  • , Ron Ram
  • , Avraham Frisch
  • , Boaz Nachmias
  • , Jonathan Canaani
  • , Yakir Moshe
  • , Baher Krayem
  • , Shlomzion Aumann
  • , Israel Henig
  • , Vladimir Vainstein
  • , Liat Shargian
  • , Chezi Ganzel
  • , Moshe Yeshurun
  • , Itay Levi
  • , Pia Raanani
  • , Luiza Akria
  • , Yishai Ofran
  • , Shai Shimony
  • Ofir Wolach
  • Rabin Medical Center Israel
  • Tel Aviv University
  • University of Texas MD Anderson Cancer Center
  • Sheba Medical Center at Tel Hashomer
  • Tel Aviv Sourasky Medical Center
  • Rambam Health Care Campus Israel
  • Technion-Israel Institute of Technology
  • Hebrew University of Jerusalem
  • Cornell University
  • Soroka Medical Center
  • Dana-Farber Cancer Institute

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Fingerprint

Dive into the research topics of 'Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia'. Together they form a unique fingerprint.
Sort by

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry

Immunology and Microbiology

Biochemistry, Genetics and Molecular Biology